The aim was to share the key highlights and value of the new connectivity solution – GEMweb Live, the newest Activated Clotting Time device on the market – GEM Hemochron 100 and the POCT solution with lab quality results for the Basic Metabolic Panel – GEM Premier ChemSTAT.
Together with the colleagues from Werfen Technology Centers in Bedford and San Diego, the EEMEA team collected feedback from the distribution partners on the positioning and discussed the unmet needs that these new solutions will fulfil in their respective markets.
With the high level of discussion and engagement of partners and considering the diversity in EEMEA countries, Werfen EEMEA Team with the colleagues from Werfen Technology Centers in Bedford and San Diego have received great insights and direction for the next steps of planning the Controlled Release for these new solutions in the coming months.
If you are interested to participate in the Controlled Release or were not able to attend the Kick-Off Meeting, please reach out to the EEMEA Acute Care Marketing Team for further information.
Poonam Rao (Acute Care Diagnostics Marketing Manager EEMEA)